Abcam plc (ABC.L) said it agreed to acquire the entire issued share capital of Epitomics International Inc. for gross consideration of $170.0 million. At completion Epitomics is expected to have net cash of $15.0 million resulting in net consideration for the acquisition of $155.0 million.
The net consideration of $155.0 million is payable 50 per cent. in cash and 50 per cent. in new Abcam shares. The new Abcam shares will be subject to a lock-up on resale that expires six months after the tender offer closes and on other restrictions on resale imposed by U.S. securities laws.
The acquisition is expected to be earnings neutral in the first full year of ownership as Abcam invests in the business to expand production and accelerate growth. The purchase is projected to be earnings enhancing in the second full year of ownership.
The deal is targeted to close in approximately one to two months' time.
Click here to receive FREE breaking news email alerts for ABCAM Plc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org